Click Here to return To Results

 

Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses Neurol 50:398-402, Achiron,A.,et al, 1998 See this aricle in Pubmed Article Abstract Treated patients showed a reduction in YER from 1.85 to 0.75 after 1 year and 0.42 after 2 years versus 1.55 and 1.8 after 1 year and 1.4 after 2 years in the placebo group(p=0.0006,overall),reflecting a 38.6%reduction in relapse rate.Six patients in the IVIg group were exacerbation free throughout the 2-year period of the study,whereas none were exacerbation free in the placebo group(p=0.003).Neurologic disability as measured by the Expanded Disability Status Scale(EDSS score)decreased by 0.3 in the IVIg group and increased by 0.15 in the placebo group.Total lesion score evaluated by brain MRI did not show a significant difference between groups.Side effects were minor and occurred in only 19 of 630(3.0%) infusions administered in both groups.Our results suggest that IVIg may be safe and effective in reducing the frequency of exacerbations of RR-MS.

Related Tags

(click to filter results - removes previous filter) disability,neurological gammaglobulin therapy,intravenous multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of pregnancy,neurologic complications in treatment of neurologic disorder

Click Here to return To Results